Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
7.69
-0.28 (-3.51%)
At close: Sep 12, 2025, 4:00 PM EDT
7.69
0.00 (0.00%)
After-hours: Sep 12, 2025, 4:00 PM EDT
Rezolute Employees
Rezolute had 59 employees as of June 30, 2024. The number of employees increased by 8 or 15.69% compared to the previous year.
Employees
59
Change (1Y)
8
Growth (1Y)
15.69%
Revenue / Employee
n/a
Profits / Employee
-$1,237,254
Market Cap
668.56M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 59 | 8 | 15.69% |
Jun 30, 2023 | 51 | 9 | 21.43% |
Jun 30, 2022 | 42 | 16 | 61.54% |
Jun 30, 2021 | 26 | 3 | 13.04% |
Jun 30, 2020 | 23 | 4 | 21.05% |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RZLT News
- 7 hours ago - Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism - GlobeNewsWire
- 16 days ago - Rezolute to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 23 days ago - Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer - GlobeNewsWire
- 7 weeks ago - Rezolute to Participate in the BTIG Virtual Biotechnology Conference - GlobeNewsWire
- 2 months ago - Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) - GlobeNewsWire
- 3 months ago - Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism - GlobeNewsWire
- 4 months ago - Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update - GlobeNewsWire